The TAXUS Express trial showed that paclitaxel-eluting stents reduced restenosis by 40% and cardiac events by 11.5%, compared to vascular brachytherapy. The benefits were achieved without compromising safety, making drug-eluting stents the new standard of care for most patients with restenosis.
Researchers have created a conveyor belt for magnetic flux vortices in superconductors, allowing them to be removed from targeted regions and improving device performance. The conveyor belt is assembled out of a line of vortices controlled by a time-varying magnetic field.
Researchers conducted a randomized trial to evaluate the effectiveness of paclitaxel-eluting stents in patients with ST-segment elevation myocardial infarction (STEMI). After one year, the study found that the drug-eluting stent reduced repeat procedures by 67% compared to bare-metal stents.
A multicenter trial found sirolimus-eluting stents to be more effective than vascular brachytherapy (VBT) in treating restenosis within a stent. The study showed significant differences in major adverse cardiac events, target lesion revascularization rates, and target vessel failure rates.
Researchers at Thomas Jefferson University Hospital found that topical lubrication improves outcomes in coronary stent procedures, particularly for patients with abnormal arteries. The study showed that lubricated stents were successfully placed in 85% of patients with no negative effects months after the procedure.
A multicenter randomized trial found that paclitaxel-eluting stents significantly reduce ischemic target vessel revascularization by 40 percent and angiographic restenosis at 9 months compared to VBT. Drug-eluting stents are now considered the treatment of choice for most patients with ISR of previously implanted bare-metal stents.
The FACTT technology has a sensitivity five orders of magnitude greater than ELISA, allowing for the detection of rare molecules at early stages. This new method holds promise for detecting abnormalities in diseases such as breast, ovarian, and pancreatic cancer.
Researchers found that GM-CSF treatment increased circulating endothelial progenitor cells, improving walking ability without pain. The therapy also showed promise for reducing vascular function risk and atherosclerosis.
Researchers developed a new method to measure EPC levels in blood samples using ALDH activity, which correlates with the degree of coronary artery disease. Patients with lower EPC levels are more likely to have greater disease and increased risk for cardiac events.
Studies investigate homocysteine lowering and cardiovascular event rates, revealing high risks for patients with atherothrombosis. Researchers explore new treatment approaches, including bone marrow mobilization, to improve exercise capacity and prevent complications.
A new analysis by Duke Clinical Research Institute researchers reveals that Lumbees have a significantly higher burden of cardiovascular risk factors. The study found that Lumbees who came to the hospital for heart treatment had higher rates of diabetes, hypertension, and prior history of coronary artery disease.
Researchers found that patients over 64, especially women and minorities, were less likely to be transferred to larger hospitals with revascularization capabilities. This disparity affects mortality rates, with transferred patients having a lower risk of death than those remaining at community hospitals.